CN114062680A - 用于可溶性成纤维细胞生长因子受体的灵敏的多重免疫测定 - Google Patents
用于可溶性成纤维细胞生长因子受体的灵敏的多重免疫测定 Download PDFInfo
- Publication number
- CN114062680A CN114062680A CN202111144712.7A CN202111144712A CN114062680A CN 114062680 A CN114062680 A CN 114062680A CN 202111144712 A CN202111144712 A CN 202111144712A CN 114062680 A CN114062680 A CN 114062680A
- Authority
- CN
- China
- Prior art keywords
- antibody
- sfgfr3
- sfgfr4
- sfgfr2
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091008794 FGF receptors Proteins 0.000 title abstract description 27
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 title abstract description 27
- 238000003018 immunoassay Methods 0.000 title description 16
- 239000004005 microsphere Substances 0.000 claims abstract description 39
- 239000012472 biological sample Substances 0.000 claims abstract description 26
- 238000001514 detection method Methods 0.000 claims description 49
- 210000002966 serum Anatomy 0.000 claims description 36
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims description 28
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims description 28
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 25
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 25
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims description 22
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims description 21
- 239000000872 buffer Substances 0.000 claims description 19
- 210000002381 plasma Anatomy 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 230000000903 blocking effect Effects 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 238000011534 incubation Methods 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 210000000941 bile Anatomy 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 210000004910 pleural fluid Anatomy 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 210000004243 sweat Anatomy 0.000 claims description 2
- 210000001179 synovial fluid Anatomy 0.000 claims description 2
- 210000001138 tear Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 21
- 238000003556 assay Methods 0.000 description 29
- 238000011084 recovery Methods 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 22
- 201000011510 cancer Diseases 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 230000027455 binding Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 239000012491 analyte Substances 0.000 description 10
- 239000012895 dilution Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 7
- 229940126864 fibroblast growth factor Drugs 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 239000004793 Polystyrene Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 229920002223 polystyrene Polymers 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 102000001301 EGF receptor Human genes 0.000 description 5
- 108060006698 EGF receptor Proteins 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101100334745 Mus musculus Fgfr4 gene Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000007837 multiplex assay Methods 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000012421 spiking Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- JLBJTVDPSNHSKJ-UHFFFAOYSA-N 4-Methylstyrene Chemical compound CC1=CC=C(C=C)C=C1 JLBJTVDPSNHSKJ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101800001224 Disintegrin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 101710182387 Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 241001296119 Panteles Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002942 anti-growth Effects 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004638 bioanalytical method Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000013931 endocrine signaling Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002907 paramagnetic material Substances 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- JJGWLCLUQNFDIS-GTSONSFRSA-M sodium;1-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 JJGWLCLUQNFDIS-GTSONSFRSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- JZBRFIUYUGTUGG-UHFFFAOYSA-J tetrapotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].[K+].[K+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JZBRFIUYUGTUGG-UHFFFAOYSA-J 0.000 description 1
- ZCUFMDLYAMJYST-UHFFFAOYSA-N thorium dioxide Chemical compound O=[Th]=O ZCUFMDLYAMJYST-UHFFFAOYSA-N 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/50—Fibroblast growth factors [FGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740466P | 2012-12-21 | 2012-12-21 | |
| US61/740466 | 2012-12-21 | ||
| CN201380073634.3A CN104995512A (zh) | 2012-12-21 | 2013-12-17 | 用于可溶性成纤维细胞生长因子受体的灵敏的多重免疫测定 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380073634.3A Division CN104995512A (zh) | 2012-12-21 | 2013-12-17 | 用于可溶性成纤维细胞生长因子受体的灵敏的多重免疫测定 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114062680A true CN114062680A (zh) | 2022-02-18 |
Family
ID=50979111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111144712.7A Pending CN114062680A (zh) | 2012-12-21 | 2013-12-17 | 用于可溶性成纤维细胞生长因子受体的灵敏的多重免疫测定 |
| CN201380073634.3A Pending CN104995512A (zh) | 2012-12-21 | 2013-12-17 | 用于可溶性成纤维细胞生长因子受体的灵敏的多重免疫测定 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380073634.3A Pending CN104995512A (zh) | 2012-12-21 | 2013-12-17 | 用于可溶性成纤维细胞生长因子受体的灵敏的多重免疫测定 |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP2936153B1 (enExample) |
| JP (2) | JP6488236B2 (enExample) |
| CN (2) | CN114062680A (enExample) |
| AU (1) | AU2013362937A1 (enExample) |
| CY (1) | CY1121482T1 (enExample) |
| DK (1) | DK2936153T3 (enExample) |
| ES (1) | ES2705328T3 (enExample) |
| HR (1) | HRP20190157T1 (enExample) |
| HU (1) | HUE042184T2 (enExample) |
| LT (1) | LT2936153T (enExample) |
| PL (1) | PL2936153T3 (enExample) |
| PT (1) | PT2936153T (enExample) |
| RS (1) | RS58147B1 (enExample) |
| SI (1) | SI2936153T1 (enExample) |
| SM (1) | SMT201900068T1 (enExample) |
| TR (1) | TR201820490T4 (enExample) |
| WO (1) | WO2014099933A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108551763B (zh) * | 2015-12-18 | 2021-11-09 | 瓦里泰细胞有限公司 | 一种确定样品中靶分子丰度的方法 |
| CN110488014A (zh) * | 2019-08-27 | 2019-11-22 | 成都和同易创生物科技有限公司 | 一种检测结直肠癌转移潜能的试剂盒及其使用方法 |
| CN116165180A (zh) * | 2022-11-16 | 2023-05-26 | 安徽恩禾生物技术有限公司 | 一种vegf荧光免疫层析测定试剂盒及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070248605A1 (en) * | 2003-12-19 | 2007-10-25 | Five Prime Therapetutics, Inc. | Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention |
| CN101201357A (zh) * | 2007-11-05 | 2008-06-18 | 广州益善生物技术有限公司 | 一种用于乳腺癌早期诊断的液相芯片试剂盒及其制备方法 |
| CN101881772A (zh) * | 2010-07-01 | 2010-11-10 | 南京工业大学 | 梅毒螺旋体(tp)抗体检验试剂盒及其制备和检测方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030008410A1 (en) * | 1995-03-13 | 2003-01-09 | Hechinger Mark K. | Immunoassay apparatus, kit and methods |
| US6632526B1 (en) * | 1997-10-14 | 2003-10-14 | Luminex Corporation | Precision fluorescently dyed particles and methods of making and using same |
| WO2005086647A2 (en) * | 2004-02-23 | 2005-09-22 | University Of Maryland, Baltimore | Immuno-pcr method for the detection of a biomolecule in a test sample |
| EP1904846A4 (en) * | 2005-06-29 | 2009-03-18 | Rules Based Medicine Inc | METHOD AND KITS FOR THE DIAGNOSIS OF ACUTE CORONARY SYNDROME |
| US8216783B2 (en) * | 2008-04-14 | 2012-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Over-expression and mutation of a tyrosine kinase receptor FGFR4 in tumors |
| CN101392172B (zh) * | 2008-11-01 | 2012-04-18 | 厦门大学 | 羧基化荧光编码微球及其合成方法 |
| CN102131524B (zh) * | 2008-11-07 | 2014-05-14 | 星系生物科技责任有限公司 | 成纤维细胞生长因子受体2的单克隆抗体 |
| EP3702371B1 (en) * | 2009-03-25 | 2022-11-02 | Genentech, Inc. | Anti-fgfr3 antibodies and methods using same |
| CN101526535B (zh) * | 2009-04-14 | 2011-04-20 | 河南省豫康生物工程技术有限公司 | 多种肿瘤标志物联合检测液相芯片及其制备方法 |
| CN101592655A (zh) * | 2009-06-23 | 2009-12-02 | 毅新兴业（北京）科技有限公司 | 液体生物芯片系统 |
| WO2012088337A1 (en) * | 2010-12-23 | 2012-06-28 | Prometheus Laboratories Inc. | Drug selection for malignant cancer therapy using antibody-based arrays |
-
2013
- 2013-12-17 SI SI201331295T patent/SI2936153T1/sl unknown
- 2013-12-17 SM SM20190068T patent/SMT201900068T1/it unknown
- 2013-12-17 RS RS20181583A patent/RS58147B1/sr unknown
- 2013-12-17 LT LTEP13865805.9T patent/LT2936153T/lt unknown
- 2013-12-17 ES ES13865805T patent/ES2705328T3/es active Active
- 2013-12-17 PT PT13865805T patent/PT2936153T/pt unknown
- 2013-12-17 JP JP2015549567A patent/JP6488236B2/ja not_active Expired - Fee Related
- 2013-12-17 CN CN202111144712.7A patent/CN114062680A/zh active Pending
- 2013-12-17 DK DK13865805.9T patent/DK2936153T3/en active
- 2013-12-17 CN CN201380073634.3A patent/CN104995512A/zh active Pending
- 2013-12-17 HU HUE13865805A patent/HUE042184T2/hu unknown
- 2013-12-17 AU AU2013362937A patent/AU2013362937A1/en not_active Abandoned
- 2013-12-17 HR HRP20190157TT patent/HRP20190157T1/hr unknown
- 2013-12-17 EP EP13865805.9A patent/EP2936153B1/en active Active
- 2013-12-17 TR TR2018/20490T patent/TR201820490T4/tr unknown
- 2013-12-17 WO PCT/US2013/075699 patent/WO2014099933A1/en not_active Ceased
- 2013-12-17 PL PL13865805T patent/PL2936153T3/pl unknown
-
2018
- 2018-10-05 JP JP2018190141A patent/JP2019053068A/ja active Pending
-
2019
- 2019-02-11 CY CY20191100179T patent/CY1121482T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070248605A1 (en) * | 2003-12-19 | 2007-10-25 | Five Prime Therapetutics, Inc. | Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention |
| CN101201357A (zh) * | 2007-11-05 | 2008-06-18 | 广州益善生物技术有限公司 | 一种用于乳腺癌早期诊断的液相芯片试剂盒及其制备方法 |
| CN101881772A (zh) * | 2010-07-01 | 2010-11-10 | 南京工业大学 | 梅毒螺旋体(tp)抗体检验试剂盒及其制备和检测方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20190157T1 (hr) | 2019-03-22 |
| PT2936153T (pt) | 2019-02-18 |
| WO2014099933A1 (en) | 2014-06-26 |
| TR201820490T4 (tr) | 2019-01-21 |
| CN104995512A (zh) | 2015-10-21 |
| AU2013362937A1 (en) | 2015-07-02 |
| EP2936153A1 (en) | 2015-10-28 |
| RS58147B1 (sr) | 2019-02-28 |
| LT2936153T (lt) | 2019-01-25 |
| EP2936153A4 (en) | 2016-05-25 |
| DK2936153T3 (en) | 2019-02-25 |
| JP2016504590A (ja) | 2016-02-12 |
| EP2936153B1 (en) | 2018-11-28 |
| JP2019053068A (ja) | 2019-04-04 |
| SMT201900068T1 (it) | 2019-02-28 |
| SI2936153T1 (sl) | 2019-02-28 |
| JP6488236B2 (ja) | 2019-03-20 |
| PL2936153T3 (pl) | 2019-05-31 |
| HK1215070A1 (en) | 2016-08-12 |
| ES2705328T3 (es) | 2019-03-22 |
| HUE042184T2 (hu) | 2019-06-28 |
| CY1121482T1 (el) | 2020-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105765386B (zh) | 用于检测中和抗体的竞争性配体结合测定法 | |
| PT92828B (pt) | Metodo de ensaio relativo a receptores de ligandos limite | |
| KR102549704B1 (ko) | Pivka-ii의 측정 방법, 및 pivka-ii 면역측정 시약 또는 키트의 제조 방법 | |
| Agnolon et al. | ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab | |
| Muñoz-San Martín et al. | Anticipating metastasis through electrochemical immunosensing of tumor hypoxia biomarkers | |
| US20210215699A1 (en) | Method for determining prostate carcinoma | |
| US20230417750A1 (en) | Single-molecule electronic multiplex nanopore immunoassays for biomarker detection | |
| CN114062680A (zh) | 用于可溶性成纤维细胞生长因子受体的灵敏的多重免疫测定 | |
| US6686167B2 (en) | Test device for detecting semen and method of use | |
| CN106680515B (zh) | 用于肺癌诊断的多分子标志物组合 | |
| US20020137097A1 (en) | Standard diluent for multiplex assays | |
| US11320427B2 (en) | Tandemly repeated antibody-binding protein and its applications | |
| JP2010091308A (ja) | レクチン吸収法による前立腺がんの診断方法及び判定キット | |
| HK40069150A (en) | Sensitive multiplex immunoassay for soluble fibroblast growth factor receptors | |
| CN105051544B (zh) | 小鼠血清中大鼠抗体的特异性检测 | |
| JP4556605B2 (ja) | 標的物質の測定方法および測定試薬 | |
| HK1215070B (en) | Sensitive multiplex immunoassay for soluble fibroblast growth factor receptors | |
| WO2019162821A1 (en) | Immunological method and kit for in vitro diagnosis of tumour and/or inflammatory diseases | |
| Wang et al. | Monoclonal antibody selection for interleukin-4 quantification using suspension arrays and forward-phase protein microarrays | |
| AU2002232578B2 (en) | Standard diluent for multiplex assays | |
| KR20240051109A (ko) | 검정 신호 증폭을 위한 방법, 조성물 및 키트 | |
| CA3247877A1 (en) | BIOMARKERS FOR DETERMINING SAMPLE SUITABILITY AND LUNG CANCER METASTASES | |
| AU2002232578A1 (en) | Standard diluent for multiplex assays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40069150 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220218 |
|
| WD01 | Invention patent application deemed withdrawn after publication |